CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: February-12-16
Credit Expiration Date: August-12-17


Skaggs School of Pharmacy and Pharmaceutical Sciences
Department of Clinical Pharmacy
Department of Physical Medicine/Rehabilitation
University of Colorado
Anschutz Medical Campus

Joel C. Marrs, PharmD, FCCP, FASHP, FNLA, BCPS-AQ Cardiology, BCACP, CLS
Associate Professor
Skaggs School of Pharmacy and Pharmaceutical Sciences
Department of Clinical Pharmacy
University of Colorado
Anschutz Medical Campus

Credit Hours

0.5 Contact Hour (0.05 CEU)



Program Description

A CPE-certified interactive newsletter with highlights from the American Society of Consultant Pharmacists workshop.

Although most AF-related strokes can be prevented with anticoagulation medication, many older adults are not receiving optimal evidence-based therapy for stroke prevention. This activity will address persistent barriers to the appropriate use of anticoagulation therapy for the prevention of stroke in AF. Consultant and senior care pharmacists are uniquely positioned to improve the outcomes of the individuals in their care, particularly with regard to tailoring appropriate anticoagulant strategies that take their patients' risk factors, comorbidities, and preferences into account.

NOTE: This activity was presented on November 1, 2015, in conjunction with ASCP's Annual Meeting and Exhibition.

Program Developer/Facilitator


Target Audience

This activity is intended for consultant and senior care pharmacists as well as other pharmacists involved or interested in senior care pharmacy and the care of older adults with atrial fibrillation.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Review guideline-recommended strategies for stratifying AF patients according to stroke risk.
  2. Identify patient subtypes who would most likely benefit from each of the approved medications for the prevention of stroke in patients with AF.
  3. Discuss situations in which the benefits of potential reversal with warfarin outweigh or do not outweigh the benefits of NOACs.
  4. Review the most up-to-date data regarding reversal agents for non-warfarin anticoagulant medications that are currently under late-stage investigation.
  5. Describe strategies for personalizing anticoagulation therapy based on individual patient and drug characteristics.
  6. Outline current evidence for prescribing aspirin for the prevention of stroke in patients with AF.


It is the policy of the ASCP to ensure balance, independence, objectivity and scientific rigor in all of its educational activities including those which are sponsored and cosponsored. All faculty are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation. The intent of this disclosure is not to prevent a presenter with significant financial interest or other relationship from making the presentation, but rather to provide the audience with information with which they can make their own judgments. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation with regard to exposition or conclusion. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.

Dr. Page: Nothing to disclose.

Dr. Marrs: Nothing to disclose.

Ms. Dechevalier has no relevant financial conflicts to disclose.

Dr. Baird has no relevant financial relationships to disclose.

Ms. McVey, MCM writer/editor, has no relevant financial conflicts to disclose.

This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Credit Statements

The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This knowledge-based activity, ACPE Universal Activity Number: 0203-9999-16-003-H01-P, has been assigned 0.5 Contact Hour (0.05 CEU).

Participants must view the activity in its entirety, successfully complete the post-test, and submit an evaluation to receive continuing pharmacy education credit.

Credit will be awarded for a score of 80% or better, and a statement may be printed immediately after passing the post-test.

For U.S. Pharmacists: Successful completion of this activity will be submitted to ACPE/NABP via CPE Monitor. Your credit will be submitted approximately 45-60 days after activity completion. It is your responsibility to provide your correct NABP e-PID and DOB (MMDD format) in your account profile.

This activity will take approximately 30 minutes to complete.

Commercial Support Statements

Supported by an educational grant from Daiichi Sankyo, Inc.


There are no fees for participating in or receiving credit for this online educational activity. This activity is designed to be completed within the time designated on this page; pharmacists should claim only those credits that reflect the time actually spent in the activity.

  1. Review the intended audience, learning objectives, and author disclosures.
  2. Study the educational content online. Be sure to review both written and audio/slide content.
  3. Once completed, continue to post-test. Online, choose the best answer to each test question. To receive a statement of credit, you must receive a passing score as designated at the top of the test. In addition, you must also complete the Activity Evaluation.
  4. Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers

Certificate Fee



The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, American Society of Consultant Pharmacists, or Daiichi Sankyo. Any medications, diagnostic procedures, or treatments discussed by the activity presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu